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Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase
Ib study to determine the maximum-tolerated dose, the dose limiting toxicities (DLT), and pharmacokinetic (PK) interaction of
docetaxel when administered in combination with pertuzumab. Initially, two dose levels of docetaxel (60 and 75 mg m2) were
explored in combination with a fixed dose of 1050 mg of pertuzumab; then two dose levels of docetaxel (75 and 100 mg m2) were
explored in combination following a fixed dose of 420 mg of pertuzumab with a loading dose of 840 mg. Both drugs were
administered intravenously every 3 weeks. The latter dose of pertuzumab was allowed after an amendment to the original protocol
when phase II data suggesting no difference in toxicity or activity between the 2 doses became available. Two patients out of two
treated at docetaxel 75 mg m2 in combination with pertuzumab 1050 mg suffered DLT (grade 3 diarrhoea and grade 4 febrile
neutropaenia). Two out of five patients treated at docetaxel 100 mg m2 in combination with pertuzumab 420 mg with a loading
dose of 840 mg suffered DLT (grade 3 fatigue and grade 4 febrile neutropaenia). Stable disease was observed at four cycles in more
than half of the patients treated and a confirmed radiological partial response with a 450% decline in PSA in a patient with hormone
refractory prostate cancer were observed. There were no pharmacokinetic drug–drug interactions. The recommended phase II dose
of this combination was docetaxel 75 mg m2 and 420 mg pertuzumab following a loading dose of 840 mg.
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The ErbB or human epidermal growth factor receptor (HER)
family of receptor tyrosine kinases are important mediators of cell
growth, survival, and differentiation (Sundaresan et al, 1998).
Although 11 ligands are known to bind to various HER family
members, none of these ligands binds directly to the human
epidermal growth factor receptor 2 (HER2). Instead, HER2
functions as a coreceptor and ligand-driven heterodimerisation
of HER2 with other HER family members appears to play an
important role in neoplastic transformation and/or progression.
Studies in cell culture systems show that heregulin-activated
HER3-HER2 heterodimers elicit the strongest proliferative and
transformation responses of any possible receptor combination
(Pinkas-Kramarski et al, 1996). Pertuzumab (Omnitargt) is a fully
humanised monoclonal antibody, which acts by blocking the
association of HER2 with other HER family members, including
the epidermal growth factor receptor, HER3 and HER4 (Adams
et al, 2006). As a result, pertuzumab inhibits ligand-initiated
intracellular signalling through two major signal pathways:
mitogen-activated protein kinase and phosphatidylinositol 3
kinase. Inhibition of these signalling pathways can result in
cell growth arrest and apoptosis, respectively (Hanahan and
Weinberg, 2000).
Pertuzumab is being developed for the treatment of patients
with solid tumours (Gordon et al, 2006; Johnson and Janne, 2006;
Walshe et al, 2006). Although both pertuzumab and trastuzumab
target HER2, they bind to distinct epitopes, and consequently,
ligand-activated downstream signalling induced by heterodimer-
isation is blocked by pertuzumab but not by trastuzumab. As a
result of these differences, pertuzumab may inhibit the growth of
tumours that do not overexpress HER2. In phase I studies,
pertuzumab was well tolerated with the most common adverse
events being fatigue, nausea, and vomiting (Agus et al, 2005).
Although, non-acneiform skin rash and diarrhoea were observed,
these were mainly grade 1, only occasionally grade 2 and did not
appear to be dose related (Laux et al, 2006). The maximum
tolerated dose was not reached with dose escalation to 15 mg kg1.
Pharmacokinetic studies indicated a terminal elimination half-life
of 2 –4 weeks supporting 3-weekly fixed dosing (Ng et al, 2006).
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Docetaxel is an antimicrotubule agent that enhances polymerisa-
tion of tubulin into stable microtubules and inhibits microtubule
depolymerisation. This leads to a disruption of the equilibrium
within the microtubule system and ultimately leads to cell death
(Rowinsky and Donehower, 1991). Docetaxel is an active drug in
various solid tumours and is also an attractive agent for
incorporation into combination regimens. In vivo studies on the
combination of pertuzumab with various cytotoxic agents,
including docetaxel, have demonstrated that there is at least an
additive anti-tumour effect without compromising the toxicity
profile. The potential improvement in anti-tumour activity to be
gained by combining pertuzumab with docetaxel, and the minimal
overlap in toxicity profiles, led to the conduct of this phase 1b
study designed to determine the maximum-tolerated dose of
pertuzumab and docetaxel when administered in combination
every 21 days. The secondary objectives were to assess the safety
and tolerability of this combination, to evaluate if there was any
pharmacokinetic interaction between pertuzumab and docetaxel
and to determine the objective responses in advanced solid
tumours.
PATIENTS AND METHODS
Patients
Patients with histologically confirmed advanced solid tumours
that had progressed during or after standard therapy or for
which no standard therapy was available were eligible for this
study. A minimum of 4 weeks had to have passed from prior
treatment with chemotherapy or radiotherapy. Patients were also
required to have a life expectancy of at least 12 weeks and a Eastern
Co-operative Oncology Group (ECOG) performance status of 0 or
1. Other eligibility criteria included adequate bone marrow
(absolute neutrophil count X1500 m3, platelet count
X100 000 m3, and haemoglobin (Hgb) X9 g dl1), renal (creati-
nine pupper normal limit or creatinine clearance of
X60 ml min1), hepatic (bilirubin pupper normal limit and
aspartate aminotransferase [AST], and alanine aminotransferase
[ALT] p2.5 times the upper limits of normal) and cardiac
(baseline left ventricular ejection fraction [LVEF] of X50%)
function and a serum calcium within normal limits. Similarly,
patients were excluded from the study if they had uncontrolled
hypertension, symptomatic CNS metastasis or neuropathyXgrade
2 according to NCI-CTC version 3.0, or any prior malignancy,
cardiac condition or serious medical illness that would affect their
management according to the study protocol. Patients were also
excluded if they had received a prior cumulative doxorubicin dose
greater than 360 mg m2 or equivalent or had a prior history of
severe hypersensitivity reactions to polysorbate 80. The institu-
tional review boards at both participating sites approved the study
protocol, and written informed consent was obtained before any
study-related procedures.
Study design and treatment
This was a phase Ib, open-label, two-center study. Pertuzumab and
docetaxel were administered as an intravenous (IV) infusion every
3 weeks. Pertuzumab was provided by F Hoffmann-La Roche
(Basel, Switzerland). Each 10 ml single-use vial contained 175 mg
of pertuzumab formulated in 10 mmol l1 L-histidine (pH6.0),
240 mmol l1 sucrose, and 0.02% polysorbate 20. The first dose of
pertuzumab was given by intravenous infusion over 90 min. If the
initial infusion was well tolerated, the infusion time was reduced to
30 min for subsequent infusions. Initially, the planned dose of
pertuzumab was fixed dose at 1050 mg for each dose level.
However, based on results of phase II single-agent studies in
metastatic breast cancer (unpublished data), ovarian cancer
(Gordon et al, 2006), and hormone refractory prostate cancer
(HRPC) (de Bono et al, 2007) which became available midway
through this study and suggested no difference in toxicity or
efficacy between the 420 and 1050 mg dose levels of pertuzumab,
the protocol was amended to fix the dose of pertuzumab at 420 mg
with a loading dose of 840 mg in cycle 1. The dose of docetaxel was
sequentially escalated from 60 to 75 to 100 mg m2 as outlined in
Table 1. The doses of pertuzumab and docetaxel were reduced,
and/or treatment cycles delayed, in patients experiencing dose-
limiting toxicities. Initially, three patients were treated in cohort 1,
with the first patient being monitored for at least 2 weeks before
additional patients were treated. Escalation to a new dose level was
permitted when at least two of three patients had been evaluated
for 3 weeks. If dose limiting toxicities (DLT) were observed during
cycle 1 in one of three patients, an additional three patients were to
be treated at that dose level. At least six patients were to be treated
at the 75 and 100 mg m2 dose levels before a recommended phase
II dose was declared. If patients withdrew for reasons other than
toxicity before completing only one cycle, they were to be replaced
at the same dose level. DLT was defined as one of the following
adverse events: (1) non-hematological toxicityXgrade 3 including
diarrhoea (except alopecia, and/or nausea and vomiting in patients
who had not received optimal treatment with antiemetics); (2)
grade 4 neutropaenia lasting at least 7 days or neutropaenia
complicated by fever or infection regardless of duration,
thrombocytopeniao25 109 l1 or any thrombocytopenia requir-
ing platelet transfusion, and (3) any subjectively intolerable
toxicity felt to be related to either one of the compounds. If DLT
was observed in X2 patients of six patients at a dose level, the
maximum-tolerated dose had been exceeded and at least six
patients would be accrued at the lower dose level to confirm that
this was the maximum-tolerated dose.
Analysis of pharmacokinetics
Pharmacokinetic (PK) assesments were performed in all patients
to determine if there was any PK interaction between pertuzumab
and docetaxel. As no dose-toxicity relationship had been demon-
strated for pertuzumab in the phase I study (Agus et al, 2005), it
Table 1 Dose escalation and dose limiting toxicity
Dose level
Pertuzumab
(mg)
Docetaxel
(mg m2)
Number of patients
planned (treated)
Number of patients
with DLT
Initial dose escalation schedule
1 1050 60 3–6 (6) 0
2 1050 75 6 (2) 2
3 1050 100 6 (0) —
Amended dose escalation schedule:
1A 840/420 60 — —
2A 840/420 75 6 (6) 0
3A 840/420 100 6 (5) 2
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was assumed that the administration of docetaxel would not lead
to a clinically relevant modification of the exposure to pertuzu-
mab. Therefore, PK assessments were focused on the potential
modification of docetaxel exposure by pertuzumab. In the first
treatment cycle, blood withdrawal for PK analysis was performed
15 and 30 min prior to administration of docetaxel and 15 and
30 min and 1, 2, 4, 8 and 23 h, post administration. Pertuzumab
was administered at least 24 h after, on day 2, followed by PK
analysis at 15 min and 1.5, 4 and 8 h. In the second cycle,
pertuzumab was administered on day 1, immediately followed by
the administration of docetaxel and sampling for PK analysis was
repeated for both drugs. Plasma samples of docetaxel were
analysed using a validated specific liquid chromatography-mass
spectrometry (LC-MS/MS) method as described previously (Agus
et al, 2005). Serum samples were assayed for pertuzumab
concentrations using a receptor-binding, enzyme-linked immuno-
sorbent assay. The assay uses immobilised antigen p185HER2 ECD
to capture pertuzumab from serum samples. Bound pertuzumab
was detected with mouse anti-human Fc-horseradish peroxidase
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA,
USA), and tetramethyl benzidine (KPL Inc., Gaithersburg, MD,
USA) used as the substrate for colour development to quantify
serum pertuzumab against a known standard curve. The assay has
a minimum quantifiable concentration of 0.25 mg ml1 for
pertuzumab in human serum. Pharmacokinetic parameters for
docetaxel and pertuzumab were estimated using non-compart-
mental methods (WinNonLin software version 5.0.1).
Tumour assessments
The response evaluation criteria in solid tumours (RECIST) were
used to assess objective response, time to disease progression, and
duration of response (Therasse et al, 2000). Tumour burden was
evaluated at baseline by physical examination and imaging
including computed tomography of chest, abdomen and pelvis,
and bone scans when clinically indicated. Responses were assessed
by identical techniques at the end (week 3) of cycles 2 and 4, and
every two cycles subsequently. Objective responses were confirmed
by repeat assessments after X4 weeks. Prostate-specific antigen
(PSA) declines or rises were described in terms of the PSA working
group criteria (Bubley et al, 1999) and CA-125 was measured in all
ovarian cancer patients and described as a percentage change from
baseline as described previously (Rustin et al, 2004).
Tolerability and safety
The incidence and severity of all adverse events, changes in vital
signs, laboratory assessments, physical examination findings, and
medical conditions during and after treatment with pertuzumab
were assessed at least weekly during the first two cycles, and at
least weekly three times thereafter, and graded according to NCI-
CTC Version 3. Laboratory evaluations included full blood count
with differential (weekly two times) and serum electrolytes,
creatinine, AST, ALT, and bilirubin before the start of every cycle.
Continued close monitoring of cardiac function was performed,
using noninvasive cardiac monitoring (two-dimensional echocardio-
graphy and Doppler or Multi-Gated Acquisition scans) every 6
weeks and reported as a change from baseline. In addition,
electrocardiographs were obtained at screening and follow-up, and
serum markers of cardiac damage (troponin T) were collected
every cycle.
RESULTS
Patient characteristics
A total of 19 patients (13 male), with a median age of 59 years
(range 22–69 years), were enrolled between April 2004 and July
2005. Nine patients (47%) had HRPC and three patients (10%) had
ovarian cancer reflecting the anticipated anti-tumour activity of
pertuzumab and docetaxel in these two tumour types. All patients
with prostate cancer were refractory to LHRH analogues and anti-
androgens and five (56%) had also developed progressive disease
while taking steroids. Seven of the patients with HRPC were
chemotherapy naive; 10 patients treated on this study had received
a median of 2 lines (range, 1–6) of prior cytotoxic chemotherapy.
Patient demographics, baseline characteristics, and prior anti-
cancer treatments are listed in Table 2.
Safety
A total of 99 treatment cycles were administered to 19
patients, with a median of 5 cycles per patient (range, 1– 15
cycles). No DLTs were observed in the first three patients treated
in cohort 1. The first two patients included in cohort 2 treated at
75 mg m2 of docetaxel and 1050 mg of pertuzumab developed
DLTs, comprising of grade 4 febrile neutropaenia (neutrophil
count 0.4 109 l1) on day 8 of the first cycle in one patient with
grade 3 diarrhoea on day 4 of the first cycle in another, lasting for 2
days resolved without sequelae after treatment with loperamide,
and grade 3 fatigue on day 6 in a second patient. As per protocol
an additional three patients were treated in cohort 1. None of
these patients developed a DLT. After a protocol amendment
six patients were recruited to cohort 2A. No DLTs were observed
and five patients were subsequently recruited and treated in
cohort 3A. Two of these patients developed DLTs in cycle 1
(grade 4 febrile neutropaenia and grade 3 fatigue) and recruitment
was discontinued. A third patient treated in cohort 3A had grade 3
stomatitis in cycle 2 requiring dose reduction. The grade 3 and 4
toxicities observed are summarised in Table 3. No infusion-related
reactions were observed. Of the 17 patients with baseline and
post-baseline cardiac function evaluations, three patients (18%)
experienced an asymptomatic LVEF decrease from baseline
of X10%: two patients in cohort 2A, one by 14% from 62 to
Table 2 Patient characteristics
Characteristics Total 19 patients
Age (years)
Median 59
Range 22–69
Sex male/female 13/6
ECOG PS
0 9
1 10
Tumour type
Prostate 9
Ovarian 3
Melanoma 2
Head and neck 1
Pancreas 1
Breast 1
Retroperitoneal paraganglioma 1
Lung 1
Prior anticancer treatment
Cytotoxic chemotherapy 10 (53%)
J1 line 4 (21.1%)
J2 lines 2 (10.5%)
J3 lines 2 (10.5%)
J4 lines 1 (5.3%)
J6 lines 1
Hormonal therapies 13 (68%)
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48% and the other from 61 to 48%, and one patient in
cohort 1, from a baseline of 77% to a value of 53%. The
former patient experienced recovery of LVEF to 53% on repeat
investigation but the latter two patients had no improvement at
final visit.
Pharmacokinetics
Pharmacokinetic parameters for pertuzumab (in the presence of
docetaxel), for 1050 mg in cycles 1 and 2 and for 840 mg cycle 1 and
420 mg cycle 2 were comparable with single agent values of
Table 3 Summary of grade 3 and 4 toxicities
Dose level
Cohort 1
(N¼6)
Cohort 2
(N¼ 2)
Cohort 2A
(N¼ 6)
Cohort 3A
(N¼ 5)
All cohorts
(N¼ 19)
All body systems
Number of patients with at least
one grade 3 or 4 toxicity
3 2 2 4 11 (58%)
Gastrointestinal disorders
Diarrhoea 2a 2a 4
Nausea 1 1
Abdominal Pain 1 1
Vomiting 1 1
Stomatitis 1a 1
General disorders
Fatigue 1a 1 1a 1a 4
Nervous system disorders
Neuropathy 1b 1
Infections
Lower respiratory tract infection 1 1
Febrile neutropaenia 1a 1a 2
Candidiasis 1 1
Cystitis 1 1
Urinary tract infection 1 1
Psychiatric disorders
Depression 1 1
aAdverse event considered to be related to the study medication. bParalysis secondary to brain metastasis.
Table 4 Summary of PK parameters for pertuzumab in combination with docetaxel
Dose (mg) Cycle
t1/2 (day) Mean
(range)
Cmax (lg ml
1)
mean (range)
AUC0-last
(lg day ml1)
mean (range)
AUC0-N
(lg day ml1)
Mean (range)
Vss (ml)
mean (range)
Cl (ml per day)
mean (range)
1050 n¼ 8 1 13.36 (7.80–19.59) 301 (143–394) 2390 (1733–3355) 3951 (2348–4980) 5214 (2975–7036) 282 (211–447)
1050 n¼ 7 2 22.08 (9.02–49.63) 368 (253–463) 3500 (3010–4346) 6856 (4521–11426) 4672 (3023–6580) 167 (92 232)
840 n¼ 11 1 12.13 (6.95–25.96) 255 (169–447) 1749 (1214–3083) 2796 (1604–5116) 5355 (3028–8217 329 (164–524)
420 n¼ 10 2 19.10 (8.85–42.00) 150 (102–233) 1491 (914–2289) 2762 (1639–3827) 4233 (2823–7058) 169 (110–256)
Table 5 Summary of PK parameters for docetaxel alone and in combination with pertuzumab
Cohort Dose group Cycle
t1/2 (h) mean
(range)
Cmax (ng ml
1)
mean (range)
AUC0-N
(ng h ml1) mean
(range)
Vss
( 104 ml m2)
mean (range)
Cl ( 103
ml h m2) mean
(range)
1 Docetaxel 60 mg m2 alone n¼ 6 1 16.9 (7.31–22.7) 1642 (1250–1960) 1838 (1523–2175) 79 (42–100) 33 (28–39)
1 Docetaxel 60 mg m2+Pertuzumab
1050 mg n¼ 6
2 19.7 (12.5–27.1) 1695 (1320–2270) 1734 (1512–2562) 102 (64–154) 36 (23–40)
2A Docetaxel 75 mg m2 alone n¼ 6 1 12.7 (9.56–19.4) 3128 (2210–4580) 3744 (2386–5783) 41 (18–70) 22 (13–31)
2A Docetaxel 75 mg m2+Pertuzumab
420 mg n¼ 6
2 15.2 (9.62–23.8) 2722 (1480–3830) 3496 (2178–5113) 57 (20–110) 24 (15–34)
3A Docetaxel 100 mg m2 alone n¼ 5 1 9.59 (7.49–13.5) 5450 (3160–7740) 5930 (3522–8364) 25 (16–32) 18 (12–28)
3A Docetaxel
100 mg m2+Pertuzumab 420 mg
n¼ 4
2 12.8 (8.04–21.4) 4705 (2210–6570) 5218 (2409–7823) 43 (16–76) 22 (12–41)
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pertuzumab from other studies at the same doses (Table 4). The
AUC0 – last was greater for cycle 2 in keeping with accumulation of
drug. The Cmax, AUC and clearance values for docetaxel alone and
in combination with pertuzumab were very similar (Table 5) and
correlated with overlapping plasma concentration time curves as
demonstrated in Figure 1, indicating no drug –drug interaction.
Anti-tumour activity
Fourteen (82.4%) of 19 patients had stable disease by RECIST
criteria after two cycles of treatment and nine (47.3%) had stable
disease after four cycles. One patient with HRPC treated in cohort
1 had stable disease by both PSAWG criteria and RECIST for 13
cycles at which time his PSA increased by 425% from baseline
although his CT scan showed stable disease. One patient with
HRPC treated in cohort 2A had a partial response by RECIST
criteria after 4 cycles, confirmed after 8 cycles of treatment. He also
had a decline in PSA by 450%. One patient in each of cohorts 2,
2A, and 3A had a confirmed PSA decline 450% in the presence of
stable disease by RECIST criteria. One ovarian cancer patient
treated in cohort 1 had a 47% decrease in CA-125 levels from
baseline after four cycles of treatment at which time she had stable
disease by RECIST and elected to stop treatment.
DISCUSSION
This study reports that the combination of pertuzumab and
docetaxel is safe with manageable side-effects. Grade 4 febrile
neutropaenia, grade 3 diarrhoea, and grade 3 fatigue were reported
DLTs. Grade 3 stomatitis in cycle 2, necessitating a dose reduction,
was observed in one patient. PK results from this study have
shown that when docetaxel and pertuzumab were concomitantly
administered, there was no apparent change in their PK. The PK
parameters were consistent with those observed in data published
previously (Bruno et al, 1998) and therefore, no drug –drug
interaction is expected. The toxicity profile of the combination was
similar to what would be expected with docetaxel alone and a dose
for the combination for future studies has been identified.
This study was not designed to identify whether an improve-
ment in the anti-tumour activity of docetaxel can be achieved by
combining this with pertuzumab. Nonetheless, stable disease at
four cycles in more than half of the patients treated, supports
further phase II evaluation of this combination in specific tumour
types. Significant anti-tumour activity has been reported with
single-agent pertuzumab in refractory ovarian cancer (Gordon
et al, 2006) and due to renewed interest in the anti-tumour activity
of docetaxel in this tumour type (Blagden and Kaye, 2005), further
investigation of docetaxel in combination with pertuzumab in
ovarian cancer patients is warranted. Ovarian cancer was however
under-represented in this study compared to HRPC in which no
evidence of anti-tumour activity was reported in a single-agent
phase II study (de Bono et al, 2007). Pertuzumab is also being
investigated in metastatic breast cancer in combination with
trastuzumab (Walshe et al, 2006) and in non small cell lung cancer
(Johnson and Janne, 2006), both tumour types in which docetaxel
is effective. Furthermore combination of pertuzumab and doc-
etaxel with agents targeting epidermal growth factor receptor and
other HER family members could overcome resistance secondary
to functional redundancy in the ErbB network (Reid et al, 2007)
and further studies of this combination with anti-tumour activity
as a primary endpoint are anticipated.
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